News

Public · Published

Guggenheim maintains Axsome Therapeutics at Buy, lowers price target to $250 from $275

Guggenheim kept its Buy rating on Axsome Therapeutics but lowered its price target to $250 from $275, a 9.1% decrease. The new target implies 83.8% upside from the November 2 close of $136.01.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on Axsome Therapeutics but lowered its price target to $250 from $275, a 9.1% decrease. The new target implies 83.8% upside from the November 2 close of $136.01.

Confirmed

Global impact / market context

A lower target still far above the current price signals the analyst expects big gains but has trimmed expectations, which means projected profits or risks were adjusted. Investors watching Axsome may compare this with other recent targets ranging from $220 to $295.

Analyst inference

Recent analyst notes on Axsome show Buy-type ratings with targets from $220 to $295, so Guggenheim's cut stays within that range. A target is an analyst's estimate of future value, not a guarantee, and the wide gap to the current price shows high uncertainty.

Analyst inference

What to watch

  1. Guggenheim's $250 target implies 83.8% upside from the November 2 close of $136.01, so watch whether the share price moves toward that level. Confirmed
  2. Watch whether other analysts follow Guggenheim by lowering their targets, since recent targets span $220 to $295 and a cluster of cuts could signal weaker shared expectations. Analyst inference
  3. Compare the reasons behind Guggenheim's target cut with Baird's $220 target and the $295 target from another firm to judge whether the change reflects company fundamentals. Proposed

Evidence

  • Original source link unavailable